	US 12,011,441 B2
	Pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
Christoph Matthias Schummer, Weilrod (DE); and Olaf Joens, Ober-Hilbersheim (DE)
Filed by Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein (DE)
Filed on Sep. 14, 2018, as Appl. No. 16/131,499.
Application 16/131,499 is a continuation of application No. PCT/EP2017/057970, filed on Apr. 4, 2017.
Claims priority of application No. 16164041 (EP), filed on Apr. 6, 2016; and application No. 16172394 (EP), filed on Jun. 1, 2016.
Prior Publication US 2019/0008863 A1, Jan. 10, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/501 (2006.01); A61K 31/50 (2006.01); A61K 31/55 (2006.01); A61K 31/635 (2006.01); A61P 9/04 (2006.01); A61K 9/20 (2006.01)

CPC A61K 31/501 (2013.01) [A61K 31/50 (2013.01); A61K 31/55 (2013.01); A61K 31/635 (2013.01); A61P 9/04 (2018.01); A61K 9/20 (2013.01); A61K 2300/00 (2013.01)]

19 Claims

1. A method of treating a dog suffering from asymptomatic (occult, preclinical) heart failure due to mitral valve disease (MVD), the method comprising administering to the dog an effective amount of a composition comprising pimobendan to effect a reduction in heart size of an already pathologically enlarged heart of the dog, wherein pimobendan is administered as two doses per day such that the total daily dosage is 0.5 mg/kg bodyweight.